On demand versus continuous use of omeprazole on reflux symptoms (3)

Not Applicable

Completed

• Conditions: Topic: Primary Care; Subtopic: Primary care; Disease: All Diseases; Digestive System

• Registration Number: ISRCTN11976737
• Lead Sponsor: Karolinska Institute

Brief Summary

2019 results presented at the American Gastroenterological association (AGA) conference in https://www.gastrojournal.org/article/S0016-5085(19)37030-1/fulltext (added 06/10/2020)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-03-05
• Study Completion: 2015-05-31
• Last Update Posted: 9 November 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 488

Inclusion Criteria

1. Age 18-65 years
2. Predominant GORD cases with heartburn and/or acid regurgitation that need PPI treatment
3. PPI responsive
4. Ability to complete questionnaires

Exclusion Criteria

1. Known Barrett’s oesophagus
2. Known severe oesophagitis (LA C or above)
3. Continuous use of NSAID/aspirin
4. Prophylactic PPI use to reduce the risk of ulcers in persons being treated with NSAIDs
5. PPI treatment to heal an ulcer induced by NSAID treatment in the last 6 months
6. PPI treatment for H. pylori eradication in the last 6 months
7. Severe disorders other than GORD with a negative impact on quality of life
8. Signs of upper gastrointestinal bleeding
9. Alarm symptoms: unintentional weight loss/vomiting/difficulties swallowing
10. Pregnancy

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Reflux symptoms; Timepoint(s): At recruitment and at 8 weeks follow up